601607 上海医药
已收盘 04-30 15:00:00
资讯
新帖
简况
每周股票复盘：上海医药（601607）一季度营收752.62亿元
证券之星 · 05-02 04:33
每周股票复盘：上海医药（601607）一季度营收752.62亿元
上海医药（601607）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 05-01 06:20
上海医药（601607）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
上海医药(02607)一季度归母净利润14.18亿元 同比增长6.35%
智通财经 · 04-29
上海医药(02607)一季度归母净利润14.18亿元 同比增长6.35%
上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参
每日经济新闻 · 04-29
上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参
每周股票复盘：上海医药（601607）泼尼松龙片通过一致性评价
证券之星 · 04-26
每周股票复盘：上海医药（601607）泼尼松龙片通过一致性评价
上海医药：附属公司泼尼松龙片通过仿制药一致性评价
财中社 · 04-24
上海医药：附属公司泼尼松龙片通过仿制药一致性评价
大摩：维持上海医药(02607)“增持”评级 目标价降至15.8港元
智通财经网 · 04-24
大摩：维持上海医药(02607)“增持”评级 目标价降至15.8港元
上海医药：公司拥有深厚的中药资源优势
每日经济新闻 · 04-23
上海医药：公司拥有深厚的中药资源优势
智通港股早知道 | 宁德时代(03750)股东询价转让A股定价为410.34元/股 氮肥价格可能进一步上涨
智通财经 · 04-21
智通港股早知道 | 宁德时代(03750)股东询价转让A股定价为410.34元/股 氮肥价格可能进一步上涨
花旗：降上海医药(02607)目标价至13.5港元 反映毛利受压 重申“买入”评级
智通财经网 · 04-14
花旗：降上海医药(02607)目标价至13.5港元 反映毛利受压 重申“买入”评级
【券商聚焦】高盛维持上海医药(02607)“沽售”评级 微升目标价至10.3元并上调净利润预测
金吾财讯 · 04-13
【券商聚焦】高盛维持上海医药(02607)“沽售”评级 微升目标价至10.3元并上调净利润预测
上海医药：公司挂牌转让上海施贵宝项目正有序推进中
每日经济新闻 · 04-09
上海医药：公司挂牌转让上海施贵宝项目正有序推进中
上海医药(601607.SH)：地高辛片通过仿制药一致性评价
智通财经 · 04-08
上海医药(601607.SH)：地高辛片通过仿制药一致性评价
上海医药：下属公司硫酸妥布霉素注射液通过仿制药一致性评价
财中社 · 04-08
上海医药：下属公司硫酸妥布霉素注射液通过仿制药一致性评价
里昂：升上海医药(02607)目标价至15.2港元 评级“跑赢大市”
智通财经 · 04-08
里昂：升上海医药(02607)目标价至15.2港元 评级“跑赢大市”
每周股票复盘：上海医药（601607）2025年归母净利润增25.74%
证券之星 · 04-05
每周股票复盘：上海医药（601607）2025年归母净利润增25.74%
上海医药发布2025年业绩报告，营收2835.52亿元，同比增长3.03%
蓝鲸财经 · 04-01
上海医药发布2025年业绩报告，营收2835.52亿元，同比增长3.03%
瑞银：升上海医药(02607)目标价至15.2港元 评级为“买入”
智通财经 · 04-01
瑞银：升上海医药(02607)目标价至15.2港元 评级为“买入”
上海医药(02607)发布2025年度业绩，归母净利润57.25亿元，同比上升25.74%
智通财经 · 03-30
上海医药(02607)发布2025年度业绩，归母净利润57.25亿元，同比上升25.74%
上海医药2025年度分红预案：拟每10股派发现金红利3.50元
美股速递 · 03-30
上海医药2025年度分红预案：拟每10股派发现金红利3.50元
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":17.09,"timestamp":1777532400000,"preClose":16.93,"halted":0,"volume":11285735,"delay":0,"changeRate":0.0095,"floatShares":2789000000,"shares":3708000000,"eps":1.5666,"marketStatus":"已收盘","change":0.16,"latestTime":"04-30 15:00:00","open":17,"high":17.12,"low":16.92,"amount":193000000,"amplitude":0.0118,"askPrice":17.09,"askSize":215,"bidPrice":17.08,"bidSize":248,"shortable":0,"etf":0,"ttmEps":1.5666,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":16.93,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":18.62,"lowLimit":15.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.82,"roa":"--","peRate":10.908975,"roe":"1.85%","epsLYR":1.54,"committee":-0.646288,"marketValue":63376000000,"turnoverRate":0.004,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-06。","hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.76,"timestamp":1777536493006,"preClose":11.7,"halted":0,"volume":7449842,"delay":0,"premium":"-39.99"},"floatMarketCap":47668000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2632647733","title":"每周股票复盘：上海医药（601607）一季度营收752.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632647733?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:33","pubTimestamp":1777667591,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，上海医药报收于17.09元，较上周的16.88元上涨1.24%。本周，上海医药4月30日盘中最高价报17.12元。本周关注点来自业绩披露要点：上海医药2026年一季报显示，一季度主营收入752.62亿元，同比上升6.36%。上海医药2026年第一季度实现营业收入752.62亿元，同比增长6.36%；归属于上市公司股东的净利润14.18亿元，同比增长6.35%。上海医药集团股份有限公司第八届董事会第三十次会议于2026年4月29日召开，会议应到董事10名，实到10名，符合法定人数要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632677836","title":"上海医药（601607）2026年一季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2632677836","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632677836?lang=zh_cn&edition=full","pubTime":"2026-05-01 06:20","pubTimestamp":1777587634,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期上海医药发布2026年一季报。截至本报告期末，公司营业总收入752.62亿元，同比上升6.36%，归母净利润14.18亿元，同比上升6.35%。本报告期上海医药盈利能力上升，毛利率同比增幅4.86%，净利率同比增幅6.05%。本次财报公布的各项数据指标表现尚佳。持有上海医药最多的基金为工银创新动力股票，目前规模为16.74亿元，最新净值1.273，较上一交易日下跌0.62%，近一年上涨16.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100004998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631598761","title":"上海医药(02607)一季度归母净利润14.18亿元 同比增长6.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631598761","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631598761?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:04","pubTimestamp":1777453483,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布2026年第一季度报告，营业收入752.62亿元(人民币，下同)，同比增长6.36%。归属于上市公司股东的净利润14.18亿元，同比增长6.35%。基本每股收益0.3823元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631537129","title":"上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2631537129","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631537129?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:04","pubTimestamp":1777417480,"startTime":"0","endTime":"0","summary":"丨2026年4月29日星期三丨NO.1泰格医药一季度净利润同比减少70.36%4月28日，泰格医药发布2026年一季报，公司实现营业收入18.01亿元，同比增加15.17%；实现归属于上市公司股东的净利润4904.31万元，同比减少70.36%；实现归属于上市公司股东的扣除非经常性损益的净利润1.20亿元，同比增加17.65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604293723254882.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293723254882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BMY","601607","09939","02607","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630047801","title":"每周股票复盘：上海医药（601607）泼尼松龙片通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2630047801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630047801?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:13","pubTimestamp":1777144390,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，上海医药报收于16.88元，较上周的16.99元下跌0.65%。本周关注点公司公告汇总：泼尼松龙片通过仿制药一致性评价，有利于提升市场竞争力公司公告汇总：泼尼松龙片一致性评价研发投入约800万元公司公告汇总：2025年大陆医院采购金额为224.7万元公司公告汇总上海医药集团股份有限公司下属天津信谊津津药业有限公司收到国家药监局颁发的泼尼松龙片《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","601607","BK0187","BK0175","BK0196","BK0184","BK0099","BK0209","BK0183","02607","BK0028","BK1197","BK0097","BK0188","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629176718","title":"上海医药：附属公司泼尼松龙片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2629176718","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629176718?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:02","pubTimestamp":1777024920,"startTime":"0","endTime":"0","summary":"4月24日，上海医药（601607/02607）发布公告，公司下属天津信谊津津药业有限公司的泼尼松龙片通过仿制药一致性评价。泼尼松龙片主要用于过敏性与自身免疫性炎症性疾病，胶原性疾病。截至本公告日，公司针对该药品的一致性评价已投入研发费用约800万元。2025年，上海医药实现收入2835.80亿元，归母净利润57.25亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243718154291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0028","BK0012","BK0020","BK1197","601607","BK0097","BK0099","BK0188","BK0196","BK0209","BK0184","02607","BK0183","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629811598","title":"大摩：维持上海医药(02607)“增持”评级 目标价降至15.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629811598","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629811598?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:40","pubTimestamp":1777020012,"startTime":"0","endTime":"0","summary":"大摩预计公司2025至28年整体盈利年复合增长率达9%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260424/20260424163026_37156.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260424/20260424163026_37156.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["601607","02607","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629351528","title":"上海医药：公司拥有深厚的中药资源优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2629351528","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629351528?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:09","pubTimestamp":1776942574,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘好,八字补肾胶囊的量价齐升,效益明显.贵司的青春宝抗衰老片作为老牌抗衰老产品，拥有近50年的市场历史和大量研究文献支持，在“气阴两虚”这一细分人群中拥有稳固的市场基础和极高的用户忠诚度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233716306035.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233716306035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0209","BK0175","BK0187","BK0099","BK0012","02607","BK0028","601607","BK0097","BK0184","BK0188","BK0196","BK1197","399319","BK0020","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629772986","title":"智通港股早知道 | 宁德时代(03750)股东询价转让A股定价为410.34元/股 氮肥价格可能进一步上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2629772986","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629772986?lang=zh_cn&edition=full","pubTime":"2026-04-21 07:28","pubTimestamp":1776727718,"startTime":"0","endTime":"0","summary":"根据2026年4月20日询价申购情况，初步确定的本次询价转让价格为410.34元/股。本次询价转让不通过集中竞价交易方式或大宗交易方式进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后6个月内不得转让。截至收盘，暗盘交易显示报价333港元，较招股价209.88港元上涨58.66%，每手100股，不计手续费，每手赚12312港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"bd99c7d8869305150ea2122170bfd90e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SNFRY","LU0823437842.USD","00719","SG9999002463.SGD","SG9999000327.SGD","601607","LU1934453819.USD","LU0611395673.USD","LU2476274308.USD","LU0251143458.SGD","BK4526","LU0651947912.USD","IE0008368742.USD","LU0543330483.HKD","00941","INTC","LU1064130708.USD","LU0516423174.USD","LU0469268626.HKD","02607","LU1770034418.SGD","LU0259732245.USD","600941","BK1191","LU0132412106.USD","LU0505663152.USD","LU1820825898.SGD","LU2041044095.USD","LU1251922891.USD","00451","LU0359201612.USD","LU0502904849.HKD","IE0032431581.USD","LU0049853897.USD","LU0048388663.USD","01093","LU1226287529.USD","LU0124384867.USD","LU1993786604.SGD","LU0370786039.SGD","LU2153592121.USD","LU0405327494.USD","LU0828237940.HKD","LU0188438112.USD","000756","LU0048575426.USD","SG9999002828.SGD","LU1102505929.USD","LU1008478684.HKD","LU1188198961.HKD","LU0593848301.USD","BK1521","LU0607220059.USD","LU0650527681.SGD","SG9999004220.SGD","LU0405327148.USD","LU0315179316.USD","LU2249611893.SGD","LU1769817179.HKD","LU2289578879.USD","LU2506952337.HKD","SGXZ49509284.SGD","LU0302445910.USD","LU0509642566.USD","LU1064131003.USD","LU0314109678.HKD","LU2039709279.SGD","LU2097828805.USD","603093","LU1226288170.HKD","SG9999001903.USD","LU0823414478.USD","LU1831875114.USD","LU0107464264.USD","LU1146622755.USD","LU1515016050.SGD","LU1226287792.SGD","LU1242518931.SGD","LU0880133367.SGD","LU1580142542.USD","SG9999003461.SGD","LU0043850808.USD","LU0128522157.USD","LU2778985437.USD","LU2242644610.SGD","LU2495084118.USD","SHPMY","LU2092937221.SGD","LU0165289439.USD","LU0326948709.USD","LU2097828557.USD","LU1303224171.USD","LU2148510915.USD","LU0348805143.USD","LU0235996351.USD","IE00B031HY20.USD","LU1861214812.USD","LU0516422366.SGD","LU1152091168.USD","BK1129","LU1813983027.USD","LU0449509016.USD","IE0003795394.USD","LU0047713382.USD","LU0214875030.USD","LU1769817096.USD","LU0143863198.USD","LU1102505762.USD","02691","03983","LU1939255532.USD","LU1152091754.HKD","LU1951186391.HKD","LU2357125470.USD","LU0823426480.USD","LU1880383440.USD","LU2153591404.USD","LU0456827905.SGD","LU0051755006.USD","LU0516423091.SGD","LU0164872284.USD","LU0106252389.USD","LU2097828714.EUR","LU2125910500.SGD","LU2348774022.SGD","LU0979878070.USD","LU1969619763.USD","LU2449936058.SGD","LU1961090484.USD","IE00B8HQ1Z84.USD","LU0210526637.USD","LU0531970944.HKD","LU1226287875.USD","LU2298321311.HKD","LU2506951792.HKD","IE00B29SXG58.USD","IE00BZ08YT58.USD","IE00BZ199S13.USD","LU2394011477.USD","LU2506952410.USD","LU0672654166.SGD","LU0106959298.USD","LU1868838027.USD","LU0871576103.HKD","LU0244354667.USD","LU0164865239.USD","LU1781817850.SGD","BK1147","LU2580892789.USD","LU1048596156.SGD","IE0008369823.USD","LU0048580855.USD","LU0821914370.USD","IE0003851619.USD","LU1023057109.AUD","SG9999001689.USD","LU0516422952.EUR","PLUG","IE00BD6J9T35.USD","BK4588","HK0000181138.USD","LU1794554557.SGD","LU0359202008.SGD","LU0149534421.HKD","LU1721428347.USD","IE00B8L5B284.USD","LU0192582467.USD","LU0181495838.USD","LU0463099449.HKD","300750","LU1328277881.USD","LU2348773727.SGD","LU2477742899.HKD","LU2506952253.HKD","BK1515","LU0011963245.USD","LU0106259558.USD","LU0327786744.USD","LU0572944931.SGD","LU2275660780.HKD","LU2476274720.SGD","BK4585","LU0828238088.HKD","LU1807302812.USD","02575","LU2097828631.EUR","EVS.SI","IE00B3M56506.USD","LU0449515922.USD","LU2125910849.SGD","LU0516422440.USD","LU0312595415.SGD","LU0328353924.USD","META","LU0228659784.USD","03393","BK0224","BK1154","LU1051769294.HKD","SG9999000459.SGD","LU0605514214.HKD","09696","LU1226288253.USD","300476","LU0501845795.SGD","LU2097828474.EUR","LU0254981946.USD","LU1997245094.SGD","LU1719994722.HKD","LU1242518857.USD","03200","SG9999001846.SGD","BK1554","LU2294711713.HKD","LU2298064838.USD","LU0320764755.SGD","LU2424517915.HKD","LU0823426308.USD","LU1255011170.USD","LU1720050803.USD","02476","LU0143863784.USD","LU0067412154.USD","LU0140636845.USD","LU0823414551.USD","LU2294711473.HKD","HK0000181112.HKD","LU0359201885.HKD","LU2328871848.SGD","BK4141","BK1610","CBLUY","06608","LU0261950470.USD","LU2152927971.USD","LU0724618433.USD","LU2298322129.HKD","LU2580892862.HKD","IE00BZ08YR35.GBP","LU0594300419.USD","LU2399975544.HKD","LU0029875118.USD","002466","LU0531971595.HKD","SG9999014674.SGD","01866","TSLA","LU1808992512.USD","LU2045819591.USD","04335","BK4519","LU3063872942.SGD","LU0326950275.SGD","LU1868837565.USD","SGXZ81163826.USD","IE00B5MMRT66.SGD","LU2360108059.USD","IE00BPRC5H50.USD","LU1039395188.USD","LU1051768304.USD","LU1979443071.USD","LU2360107325.USD","LU1880383366.USD","LU0039217434.USD","BK1116","LU0231483743.USD","LU0072913022.USD","LU0594300179.USD","LU0828237510.HKD","IE00BZ08YS42.EUR","LU1960683339.HKD","301200","LU1997244956.HKD","00297","LU0054450605.USD","LU0651946864.USD","LU0455707207.USD","HK0000165453.HKD","LU1997245177.USD","LU1861219969.SGD","COIN","03750","BK1594","LU1655091616.SGD","LU1978683503.SGD","LU2238339852.HKD","IE00B543WZ88.USD","LU0072462343.USD","LU1048588211.SGD","LU0269904917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627415721","title":"花旗：降上海医药(02607)目标价至13.5港元 反映毛利受压 重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2627415721","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627415721?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:33","pubTimestamp":1776152029,"startTime":"0","endTime":"0","summary":"该行认为，管理层执行风险、整合进度慢于预期，及处方药网上销售放宽政策出台慢于预期等，均为下行风险。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260414/20260414153119_10699.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260414/20260414153119_10699.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627816804","title":"【券商聚焦】高盛维持上海医药(02607)“沽售”评级 微升目标价至10.3元并上调净利润预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2627816804","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627816804?lang=zh_cn&edition=full","pubTime":"2026-04-13 13:32","pubTimestamp":1776058351,"startTime":"0","endTime":"0","summary":"金吾财讯 | 高盛发表研报指，上海医药(02607)第四季收入685亿元，按年增长4.4%，高于该行预期的659亿元，主要由制造业务板块的稳健表现带动；同期净利润为5.78亿元，按年增长16%，低于该行预期的12亿元，主要由于创新药商业化带动销售开支大幅增加，以及期内确认的投资损失及资产减值。该行将其2026至2027年净利润预测分别上调5.8%及1.7%，以反映销售开支增加及上海和黄药业的合并，引入2028年每股盈利预测1.06元；目标价由10.03港元上调至10.3港元，维持“沽售”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978745","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902114","title":"上海医药：公司挂牌转让上海施贵宝项目正有序推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902114","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902114?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:15","pubTimestamp":1775722547,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问公司挂牌转让所持上海施贵宝股份进展如何？公司今年对创新药研发计划投入由增加吗？上海医药（601607.SH）4月9日在投资者互动平台表示，公司挂牌转让上海施贵宝项目正有序推进中，相关交易进展公司会按照监管要求及时履行信息披露义务，请您继续关注公司公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699584342.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699584342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","LU1868836757.USD","BK4534","LU1670711040.USD","LU1291159041.SGD","LU0225771236.USD","LU1093756325.SGD","601607","LU1261432733.SGD","LU1868837136.USD","LU2125154935.USD","LU1670711123.USD","LU1032466523.USD","LU0096364046.USD","BK0209","LU0114720955.EUR","LU1585245621.USD","LU1868837300.USD","BK0183","BK4532","BK0028","LU0237698245.USD","LU1883839398.USD","BK4585","LU2360032135.SGD","LU0267386448.USD","LU0061475181.USD","LU0321505868.SGD","LU1074936037.SGD","LU2242646821.SGD","LU0306807586.USD","BK4588","BK0184","BMY","LU0321505439.SGD","IE00BFTCPJ56.SGD","LU2242652126.USD","BK4559","IE00B2B36J28.USD","LU1868836914.USD","LU2133065610.SGD","LU0985481810.HKD","BK0012","BK0187","02607","BK1197","LU0882574055.USD","BK0188","IE00BJJMRZ35.SGD","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625916959","title":"上海医药(601607.SH)：地高辛片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2625916959","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625916959?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:04","pubTimestamp":1775635449,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，公司下属上海上药信谊药厂有限公司的地高辛片收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通过仿制药一致性评价。地高辛片适用于1、治疗成人轻度至中度心力衰竭。地高辛可增加左心室射血分数并改善心力衰竭症状，表现为提高运动能力和减少心力衰竭相关住院和急诊治疗，而对死亡率无影响。在可能的情况下，地高辛应与利尿剂和血管紧张素转换酶抑制剂联合使用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0099","BK0028","BK0097","BK0184","02607","601607","BK0183","BK0187","BK0196","BK1197","BK0012","BK0209","BK0020","BK0188","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625916857","title":"上海医药：下属公司硫酸妥布霉素注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2625916857","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625916857?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:50","pubTimestamp":1775634600,"startTime":"0","endTime":"0","summary":"4月8日，上海医药（601607/02607）发布公告，近日，公司下属上药禾丰的硫酸妥布霉素注射液收到国家药监局颁发的《药品补充申请批准通知书》，该药品通过仿制药一致性评价。该药品的规格为2ml：80mg，适用于多种感染症状。2025年1月，上药禾丰向国家药监局提出了该药品的一致性评价补充申请，并获得受理，相关研发费用约为438万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698020185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0028","BK0184","BK1197","BK0012","BK0099","BK0209","BK0183","601607","BK0020","BK0188","BK0097","BK0187","BK0196","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625991306","title":"里昂：升上海医药(02607)目标价至15.2港元 评级“跑赢大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2625991306","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625991306?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:28","pubTimestamp":1775633337,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，上海医药(02607) 2025财年收入2,836亿元人民币，同比增加3%，净利润57.3亿元人民币，同比增加25.7%，均与市场预期基本一致。中药一直是公司生产业务的核心驱动力，公司将继续优先发展创新药物研发以推动增长。该行将其目标价由14.2港元上调至15.2港元，维持“跑赢大市”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","EWH","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625061631","title":"每周股票复盘：上海医药（601607）2025年归母净利润增25.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625061631","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625061631?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:52","pubTimestamp":1775325130,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，上海医药报收于17.31元，较上周的16.69元上涨3.71%。本周，上海医药4月2日盘中最高价报17.37元。3月30日盘中最低价报16.54元。上海医药当前最新总市值641.92亿元，在医药商业板块市值排名1/32，在两市A股市值排名286/5193。2025年第四季度，公司单季度主营收入685.07亿元，同比上升4.4%；单季度归母净利润5.77亿元，同比上升15.88%；单季度扣非净利润2.82亿元，同比下降25.65%。负债率61.49%，投资收益31.7亿元，财务费用14.07亿元，毛利率10.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624466592","title":"上海医药发布2025年业绩报告，营收2835.52亿元，同比增长3.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624466592","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624466592?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:35","pubTimestamp":1775039711,"startTime":"0","endTime":"0","summary":"财报显示，公司实现营业收入2835.52亿元，同比增长3.03%；归母净利润57.25亿元，同比增长25.74%。扣非归母净利润为29.80亿元，同比下降26.68%；若进一步剔除非经常性损益影响，扣非后归母净利润为47.21亿元，同比下降5.56%。销售费用达132.06亿元，同比增长3.87%。经营活动现金流净额为61.54亿元，同比增长5.61%。分红方面，公司2025年度拟派发现金红利12.98亿元，叠加半年度已派发的4.45亿元，累计派现17.43亿元，占归母净利润的30.45%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775036336712856794","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624532596","title":"瑞银：升上海医药(02607)目标价至15.2港元 评级为“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2624532596","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624532596?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:38","pubTimestamp":1775032694,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，上海医药(02607)去年总收入同比升3%至2,840亿元人民币，纯利同比升25.7%至57.2亿元，经常性纯利同比跌26.7%至29.8亿元人民币，大致上符合预期。将上海医药2026至2028年盈利预测下调1%至上调3%，目标价由15港元上调至15.2港元，评级“买入”。该行指出，考虑到上海医药的定位策略、多元化业务以及在快速增长业务中的竞争优势，该行预计上海医药在“十五五”期间的增长将超越其医药分销同行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","EWH","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623634353","title":"上海医药(02607)发布2025年度业绩，归母净利润57.25亿元，同比上升25.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623634353","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623634353?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:12","pubTimestamp":1774876356,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布2025年度业绩，营业收入2835.80亿元，同比增长3.03%。其中：医药工业实现销售收入245.22亿元，同比增长3.33%;医药商业实现销售收入2590.58亿元，同比增长3.00%。归属于上市公司股东的净利润57.25亿元，同比上升25.74%。归属于上市公司股东的净利润同比上升，主要是由于对和黄药业会计核算由合营企业权益法核算变更为子公司核算所产生的一次性特殊收益所致，扣除上述事项等一次性特殊损益后的归母净利润为47.21亿元，同比下降5.56%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137199609","title":"上海医药2025年度分红预案：拟每10股派发现金红利3.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137199609","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137199609?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:46","pubTimestamp":1774874806,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司（以下简称“上海医药”）近日披露2025年度利润分配预案，公司计划向全体股东每10股派发现金红利3.50元（含税）。该分红方案体现了公司稳健的盈利能力和回报股东的诚意，若顺利实施，将进一步提升股东权益价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0097","BK0184","BK0183","BK0012","601607","BK0196","BK0099","BK0020","BK0187","BK0209","BK0028","BK0188","BK0175"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777764212584,"stockEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.0023},{"period":"3month","weight":-0.0121},{"period":"6month","weight":-0.0409},{"period":"1year","weight":-0.0272},{"period":"ytd","weight":-0.0366}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"100447人(较上一季度增加Infinity%)","perCapita":"27767股","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}